news
GLP-1 treatment displays best-in-class potential for MASH
These results from the Phase II trial could lead to clinically meaningful benefits for cardiovascular, renal, and metabolic diseases, Boehringer Ingelheim suggests.
List view / Grid view
fibrosis
news
FDA approval could shape liver disease treatment landscape
A novel liver therapy authorised under US Food and Drug Administration (FDA) Accelerated Approval, is a potential game-changer in the NASH treatment space.
news
First AI-generated small molecule drug enters Phase II trial
Insilico Medicine’s novel AI-generated small molecule inhibitor drug represents a new milestone in pharmaceutical drug development.
news
Aramchol™ reduces fibrosis progression in 24 weeks
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.
news
Crystallised drug formulation extends medical device function
A study has shown that crystallising drugs removes localised immune reaction, allowing long-term release of drugs from medical devices.
